Bionano Genomics Reports First Quarter 2021 Financial Results and Highlights Recent Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
BioNano Genomics, Inc. (BNGO) Reports Q1 EPS of $0.00
May 13, 2021 4:35 PM EDTBioNano Genomics, Inc. (NASDAQ: BNGO) reported Q1 revenue $3.2 million versus the consensus estimate of $2.9 million.
2021 is off to a solid start for Bionano. In the first quarter, we sold a record number of flow cells, analyzed a record number of samples in our service lab, drove broad adoption of Saphyr instruments and ramped up the installation of Saphyr systems that werent yet operational because of 2020s travel restrictions, said Erik Holmlin, PhD, CEO of Bionano. With the largest number of Saphyr systems in service... More
